Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
Divaya Bhutani, Jeffrey A Zonder Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the s...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3d0a108b5d134eb4907426eb0441eb80 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|